A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients
暂无分享,去创建一个
Joseph O. Deasy | Jose Belderbos | Philippe Lambin | Andreas Rimner | Cary Oberije | Dirk De Ruysscher | Ruud Houben | Anne-Marie C. Dingemans | P. Lambin | J. Deasy | D. de Ruysscher | C. Oberije | J. Belderbos | A. Dingemans | A. Rimner | R. Houben | Wilma Uyterlinde | Michel van de Heuvel | Shaun Din | W. Uyterlinde | M. M. van de Heuvel | S. Din
[1] D. de Ruysscher,et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[3] P. Baas,et al. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. , 2013, Clinical lung cancer.
[4] P. Lambin,et al. The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] P. Lambin,et al. Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. , 2012, European journal of cancer.
[6] V. Preedy,et al. Recursive Partitioning Analysis , 2010 .
[7] H. Bartelink,et al. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. , 2000, European journal of cancer.
[8] M. J. Solan,et al. Prognostic factors in non-small cell lung cancer. , 2003, Seminars in surgical oncology.
[9] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[10] Martha Sajatovic,et al. Clinical Prediction Models , 2013 .
[11] P. Lambin,et al. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.
[12] E. Yorke,et al. Involved-field radiation therapy for inoperable non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] B. Asselain,et al. 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. , 2006, The Lancet. Oncology.
[14] E. Steyerberg,et al. [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.
[15] J F Fowler,et al. Biological Factors Influencing Optimum Fractionation in Radiation Therapy , 2001, Acta oncologica.
[16] Maria Werner-Wasik,et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.
[17] H. Fukuda,et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .
[18] D. Mark,et al. Clinical prediction models: are we building better mousetraps? , 2003, Journal of the American College of Cardiology.
[19] P. Lambin,et al. Predicting outcomes in radiation oncology—multifactorial decision support systems , 2013, Nature Reviews Clinical Oncology.
[20] M. Brundage,et al. Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.
[21] Thomas J. Smith,et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M Oudkerk,et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] C. Ling,et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.
[24] Shipeng Yu,et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. , 2009, International journal of radiation oncology, biology, physics.
[25] Patrick Granton,et al. Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.
[26] Philippe Lambin,et al. Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[27] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.
[28] Philippe Lambin,et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] W. Curran,et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. , 2005, International journal of radiation oncology, biology, physics.
[30] W. Sause,et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. , 2000, International journal of radiation oncology, biology, physics.
[31] Andrew Jackson,et al. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[32] T. Pajak,et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. , 1993, International journal of radiation oncology, biology, physics.
[34] P. Lambin,et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. , 2008, International journal of radiation oncology, biology, physics.
[35] V. Budach,et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[36] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[37] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[38] H. Akaike. A new look at the statistical model identification , 1974 .
[39] Tae Hyun Kim,et al. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. , 2014, International journal of radiation oncology, biology, physics.
[40] R. Weichselbaum,et al. The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy. , 2014, Clinical lung cancer.
[41] E. Yorke,et al. Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. , 2010, International journal of radiation oncology, biology, physics.
[42] David R. Anderson,et al. Model Selection and Multimodel Inference , 2003 .
[43] D. Cox. Note on Grouping , 1957 .
[44] Jing Zhao,et al. Radiation dose effect in locally advanced non-small cell lung cancer. , 2014, Journal of thoracic disease.
[45] Yoshinao Abe,et al. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. , 2006, International journal of radiation oncology, biology, physics.
[46] P. Lambin,et al. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). , 2011, International journal of radiation oncology, biology, physics.
[47] Marianne Paesmans,et al. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables , 2011, Therapeutic advances in medical oncology.